November 2, 2017
11 am to 12 pm EST

Sponsored by



Webinar Description:

Human Induced Pluripotent Stem Cells (hiPSCs) and their derivatives have promising potentials in regenerative medicine. It is imperative to be able to manipulate the gene expression in iPSCs and their derived cell lines. To date, low transfection rates in these cells have been a barrier to their therapeutic use and applications. Through the use of the MaxCyte STX Platform, we have demonstrated at least 80% to 90% transfection efficiency in hiPSCs and iPSC-derived cell lines, including neural progenitor cells, motor neurons, and cardiomyocytes. The high transfection efficiency of plasmid DNA expressing sgRNA/Cas9 improved the efficiency to edit/modify genomic DNA in hiPSCs by up to 10-fold. Consistent gene overexpression over a period of 2-4 weeks in differentiated cells, such as iPSC-derived cortical neurons, motor neurons, and cardiomyocyte precursor cells, provides a powerful tool to determine the gene of interest during differentiation and/or maturation processes. This webinar will discuss the methods and results of iPSC transfection along with platform comparisons using iPSC-derived cell lines in iXCells Biotechnologies’ stem cell programs.


Nianwei LinDr. Nianwei Lin, Ph.D.

Chief Operating Office, VP, and Co-Founder

iXCells Biotechnologies

PhD from the University of Florida College of Medicine in Genetics, Postdoctoral Fellow at the Sanford-Burnham Medical Research Institute, WRD Postdoctoral Fellow at Pfizer in La Jolla, CA